Table 3.
Intralesional immunotherapy for warts
| Study | Antigen/vaccine | Maximum number of sessions | Interval between two sessions (week/s) | Complete response rate (%) | Adverse effects |
|---|---|---|---|---|---|
| Johnson et al.[5] | Mumps or Candida | 3 | 3 | 74 | Immediate pain, pruritus |
| Sharquie et al.[7] | BCG vaccine | 3 | 4 | 40 | Nil |
| Nofal and Nofal[9] | MMR vaccine | 5 | 2 | 85 | Flu-like symptoms, erythema, edema, pain, and itching |
| Saoji et al.[20] | PPD | 4 | 2 | 76 | Erythema, edema, pain |
| Singh et al.[10] | Mycobacterium w | 10 | 2 | 55 | Intradermal granuloma, pain paresthesia, atrophic scarring |
| Present study | BCG vaccine | 3 | 3 | 74 | Immediate pain, flu-like symptoms, erythema, edema, BCGitis |
BCG: Bacillus Calmette-Guerin, MMR: Measles, Mumps, Rubella, PPD: Purified protein derivative